BRIEF-Amarin reduces it cardiovascular outcomes study of Vascepa
September 12, 2016 at 05:59 AM EDT
* It cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|